Scarica l'app Stockscreener
36.79
167.18%
23.02
Dopo l'orario di chiusura:
36.68
-0.11
-0.30%
Precedente Chiudi:
$13.77
Aprire:
$45.96
Volume 24 ore:
27.54M
Relative Volume:
44.97
Capitalizzazione di mercato:
$1.39B
Reddito:
-
Utile/perdita netta:
$-63.78M
Rapporto P/E:
-13.73
EPS:
-2.68
Flusso di cassa netto:
$-53.91M
1 W Prestazione:
+171.71%
1M Prestazione:
+193.38%
6M Prestazione:
+225.86%
1 anno Prestazione:
+96.42%
Intervallo 1D:
$35.00
$46.42
Intervallo di 1 settimana:
$13.50
$46.42
Portata 52W:
$7.575
$46.42
Celcuity Inc Stock (CELC) Company Profile
Nome
Celcuity Inc
Settore
Industria
Telefono
763-392-0767
Indirizzo
16305 36TH AVENUE N, MINNEAPOLIS, MN
Confronta CELC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
36.79 | 521.42M | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Ripresa | Stifel | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-02-22 | Iniziato | Stifel | Buy |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-07 | Iniziato | Jefferies | Buy |
| 2021-07-29 | Iniziato | Cowen | Outperform |
| 2021-07-27 | Iniziato | Needham | Buy |
| 2021-01-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-11 | Ripresa | Craig Hallum | Buy |
| 2018-11-20 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Celcuity Inc Borsa (CELC) Ultime notizie
Celcuity announces $225M combined offerings; shares down - MSN
Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - GlobeNewswire
Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win - insights.citeline.com
Celcuity rockets after positive trial results on breast cancer combo treatment - Sherwood News
Celcuity announces $225 million in proposed public offerings - Investing.com
Geda load of this: Celcuity rocks breast cancer phase III - BioWorld MedTech
Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success - Invezz
Celcuity Inc (CELC) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Celcuity price target raised to $60 from $28 at Leerink - TipRanks
Celcuity stock rallies on Phase III breast cancer trial progress - Yahoo Finance
Celcuity's triple cancer drug combo beats AstraZeneca in halting cancer progression, shows study - Mint
Celcuity shares triple on late-stage results for breast cancer therapy - BioPharma Dive
Celcuity rockets on new gedatolisib data - The Pharma Letter
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress - ACCESS Newswire
Celcuity Stock (NASDAQ: CELC) shares Skyrockets 210% on Breakthrough Breast Cancer Trial Results | Celcuity Stock Price - paginasiete.bo
Biotech Stock Blasting Off After Late-Stage Trial Results - Schaeffer's Investment Research
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday - 富途牛牛
Celcuity Stock Triples on Positive Breast Cancer Treatment Study - Investopedia
Celcuity's Breast Cancer Drug Trial Shows 210% Stock Surge - AInvest
Celcuity Skyrockets 214%: Can This Biotech Breakout Sustain Momentum? - AInvest
This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why - Stocktwits
Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer - Benzinga
Lawmakers demand crackdown on surge in counterfeit weight loss drugs - statnews.com
Why Is Celcuity Stock (CELC) Up 210% Today? - TipRanks
Why is CELC Skyrocketing in Premarket Trading Today? - Tokenist
Celcuity stock soars after breast cancer drug shows 76% risk reduction - Fingerlakes1.com
Celcuity Announces Positive Phase 3 Trial Results - TipRanks
Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study - TradingView
Will Celcuity Inc. continue its uptrendAI Generated Buy/Sell Signal Forecast - Newser
Celcuity's Gedatolisib: A Paradigm Shift in HR+/HER2- Advanced Breast Cancer Treatment - AInvest
Relative strength of Celcuity Inc. in sector analysisFree Earnings Play Trade Plan With Alerts - Newser
Celcuity Soars 112.27% on Positive Breast Cancer Trial Results - AInvest
Celcuity stock soars after breakthrough breast cancer drug trial results By Investing.com - Investing.com Nigeria
Celcuity stock soars after breakthrough breast cancer drug trial results - Investing.com
Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ('PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial - The Manila Times
Celcuity reports breakthrough breast cancer treatment results By Investing.com - Investing.com India
Celcuity reports breakthrough breast cancer treatment results - Investing.com
Breakthrough: New Breast Cancer Drug Quadruples Survival Time in Phase 3 Trial, Sets Historic Efficacy Record - Stock Titan
Does Celcuity Inc. stock perform well during market downturnsFind market-beating stocks for your portfolio - jammulinksnews.com
Celcuity's gedatolisib combo succeeds in pivotal breast cancer study - FirstWord Pharma
Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Roche - Endpoints News
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - inkl
Celcuity Stock Soars 10.24% Ahead of Breast Cancer Trial Results - AInvest
Can Celcuity Inc. recover in the next quarter Fast Return Equity Forecast With Logic - Newser
Why is Celcuity Inc. stock attracting strong analyst attentionGet daily updates on promising stocks - jammulinksnews.com
How does Celcuity Inc. compare to its industry peersUnlock powerful trading tools for investors - jammulinksnews.com
Is Celcuity Inc. stock a good hedge against inflationHigh Reward Swing Trades - Newser
Is Celcuity Inc. a Top Dividend Stock to Watch in 2025Free Stock Selection with 300% Return - Newser
Is Celcuity Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Professional Trading Signals - Newser
Sectors Driving Future Growth for Celcuity Inc. StockFree Capital Growth Strategies - Newser
Celcuity Inc. Company Revenue and Profit Trends: A Deep DiveFree Stock Trading Signals - Newser
Celcuity Inc Azioni (CELC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.32%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):